Commentary - (2022) Volume 14, Issue 1
Cancer is linked to ageing, which is a well-known risk factor. Because of the growing senior population, the number of new cancer diagnoses has increased globally. Many theories have been proposed over the years to explain this increased risk, including higher genetic and epigenetic alterations, as well as the idea of immunosenescence. The best therapeutic options for this cancer-stricken population are unknown. Older cancer patients have historically been underrepresented in clinical trials designed to establish best practises, resulting in undertreatment or higher toxicity. With this in mind, it's critical to look into new anti-cancer agents, such as immune-checkpoint inhibitors, that have recently been discovered, in order to manage these daily clinical issues and eventually combine them with alternative antiblastic drug administration strategies, such as metronomic chemotherapy.
Older patients • Cancer • Immunosenesce • Metronomic chemotherapy • Immunotherapy
Citation: Johnson E. Time to Test More Anti-Cancer Treatment Strategies in the Elderly. Int. J. Collab. Res. Intern. Med. Public Health. 2022, 14 (01), 001-003
Received: 22-Jan-2022 Published: 31-Jan-2022
Copyright: 2022 Johnson E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Sources of funding : none
